What pharmacologic options are appropriate for treating insomnia in a patient currently taking buspirone 5 mg, lorazepam (Ativan) 0.5 mg, and mirtazapine (Remeron) 30 mg?

Recommended Pharmacologic Options for Insomnia

Given this patient's current regimen (buspirone 5 mg, lorazepam 0.5 mg, mirtazapine 30 mg), I would first optimize the mirtazapine dose for insomnia before adding another agent, as the patient is already on a sedating antidepressant that treats insomnia. However, if additional pharmacotherapy is needed, the preferred options are short/intermediate-acting benzodiazepine receptor agonists (BzRAs) such as zolpidem, eszopiclone, or zaleplon, or alternatively ramelteon or low-dose doxepin.

Critical Context: Current Medication Considerations

Before prescribing additional insomnia treatment, several important factors must be addressed:

Mirtazapine (Remeron 30 mg)

• The patient is already taking mirtazapine 30 mg, which has significant sedating properties through H1-receptor antagonism 1
• Mirtazapine at this dose is commonly used off-label for insomnia and recent evidence shows it significantly reduces insomnia severity in older adults (mean ISI reduction of -6.5 points vs -2.9 for placebo, p=0.003) 2
• If insomnia persists despite mirtazapine 30 mg, consider whether the dose timing is optimized (should be taken at bedtime) or if the dose could be adjusted
• Important caveat: Mirtazapine can cause daytime sedation, confusion in elderly patients, and has risks for hyponatremia, particularly in older adults 1

Lorazepam (Ativan 0.5 mg)

• This benzodiazepine is already in the regimen and may be contributing to insomnia treatment
• However, lorazepam has a concerning profile for chronic insomnia: it can cause rebound anxiety near the end of its metabolic activity, potentially worsening both anxiety and sleep 3
• Consider tapering lorazepam if adding another hypnotic, as combining multiple sedatives increases risks of cognitive impairment, falls, and respiratory depression
• The 2017 AASM guidelines note that benzodiazepines like temazepam and triazolam have evidence for insomnia, but lorazepam specifically is not among the recommended agents 4

Buspirone (5 mg)

• Buspirone has stimulant properties and can worsen insomnia - it increases wake time after sleep onset, particularly during initial administration 5
• This medication may be counterproductive for sleep and should be evaluated for necessity
• If anxiety is the primary indication, consider whether the mirtazapine (which has anxiolytic properties through 5-HT2 receptor antagonism) could address this 6

First-Line Pharmacologic Recommendations

Based on 2017 AASM guidelines (the most recent comprehensive guideline), the following agents receive weak recommendations for insomnia treatment 4:

BzRAs (Benzodiazepine Receptor Agonists) - Preferred First-Line

For sleep onset insomnia:

• Zaleplon 10 mg at bedtime 4
• Zolpidem 10 mg at bedtime (also effective for sleep maintenance) 4
• Triazolam 0.25 mg at bedtime 4

For sleep maintenance insomnia:

• Eszopiclone 2-3 mg at bedtime (also effective for sleep onset) 4
• Zolpidem 10 mg at bedtime 4
• Temazepam 15 mg at bedtime 4

Clinical considerations for BzRAs:

• These agents should be used cautiously given the patient is already on lorazepam - strongly consider tapering lorazepam first
• Risk of complex sleep behaviors (sleep-driving, sleep-eating) - patients must be counseled 7
• Lower doses required in elderly and those with hepatic/renal impairment 7
• Avoid alcohol and allow adequate sleep time (7-8 hours) 7
• FDA mandates lower doses for women with zolpidem preparations due to morning carry-over effects 8

Alternative First-Line Options

Ramelteon 8 mg at bedtime 4

• Melatonin receptor agonist, primarily for sleep onset insomnia
• No abuse potential, no short-term usage restrictions
• May be preferable given patient's existing sedative load
• Safer option with fewer drug interactions

Suvorexant (orexin receptor antagonist) 4

• Doses of 10,15/20, or 20 mg for sleep maintenance insomnia
• Newer mechanism of action
• May cause next-day somnolence at higher doses

Low-dose doxepin 3-6 mg at bedtime 4

• Specifically for sleep maintenance insomnia
• Different mechanism than mirtazapine (H1 antagonism at low doses)
• Caution: Combining two sedating antidepressants increases anticholinergic burden and sedation risk

Agents to AVOID

The 2017 AASM guidelines specifically recommend AGAINST the following 4:

• Trazodone - insufficient evidence despite widespread off-label use
• Diphenhydramine (OTC antihistamines) - lack of efficacy data, anticholinergic risks
• Melatonin (OTC formulations) - insufficient evidence at 2 mg doses
• Tiagabine - harms outweigh benefits
• L-tryptophan and valerian - insufficient evidence

Recommended Clinical Algorithm

Step 1: Optimize Current Regimen

• Ensure mirtazapine 30 mg is taken at bedtime
• Evaluate necessity of buspirone (may worsen insomnia) 5
• Consider tapering lorazepam given its problematic profile for chronic insomnia 3

Step 2: If Additional Pharmacotherapy Needed

For sleep onset insomnia:

• First choice: Ramelteon 8 mg (safest given current medications)
• Alternative: Zaleplon 10 mg or Zolpidem 10 mg (if lorazepam tapered)

For sleep maintenance insomnia:

• First choice: Eszopiclone 2-3 mg (if lorazepam tapered)
• Alternative: Suvorexant 10-20 mg
• Consider: Low-dose doxepin 3-6 mg (though adds to sedating antidepressant burden)

Step 3: Monitoring and Follow-up

• Reassess every few weeks initially for effectiveness and side effects 7
• Monitor for cognitive impairment, falls risk (especially if elderly), and daytime sedation
• Attempt to use lowest effective dose and consider intermittent dosing (3 nights/week) for long-term use 7
• Strongly consider cognitive behavioral therapy for insomnia (CBT-I) as adjunct or alternative - this is the standard of care and facilitates medication tapering 4, 9

Critical Safety Warnings

Drug Interactions:

• Combining multiple CNS depressants (mirtazapine + lorazepam + new hypnotic) significantly increases risks 7, 1
• Mirtazapine can interact with other serotonergic agents - monitor for serotonin syndrome 1
• All hypnotics have additive effects with alcohol and other sedatives 7

Special Populations:

• Elderly: Require dose reductions, higher fall risk, increased confusion risk with sedatives 7, 1
• Hepatic/renal impairment: Mirtazapine clearance already reduced; additional hypnotics require dose adjustment 1

Common Pitfall: The patient is already on three medications that can affect sleep/sedation. Adding a fourth agent without optimizing or rationalizing the existing regimen increases polypharmacy risks without necessarily improving outcomes. The evidence-based approach is to optimize mirtazapine timing/dosing and taper problematic agents (buspirone, lorazepam) before adding new hypnotics 7.